|
|
|
27.06.25 - 22:03
|
Xenon Joins the Russell 3000® and Russell 2000® Indexes (GlobeNewswire EN)
|
|
|
VANCOUVER, British Columbia and BOSTON, June 27, 2025 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to discovering, developing, and delivering life-changing therapeutics for patients in need, today announced that the company has been added to the broad-market Russell 3000® and small-cap Russell 2000® Indexes as part of the annual reconstitution, effective at the close of U.S. equity markets on Friday, June 27, 2025....
|
|
|
26.06.25 - 22:03
|
Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire EN)
|
|
|
VANCOUVER, British Columbia and BOSTON, June 26, 2025 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to discovering, developing, and delivering life-changing therapeutics for patients in need, today announced equity inducement grants to six new non-officer employees consisting of an aggregate of 24,750 share options. All of the foregoing share options were approved by the Compensation Committee of the Company's Board of Directors with an effective date of June 23, 2025 and were granted as inducements material to the employees entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4)....
|
|
|
|
|
|
|
03.06.25 - 22:03
|
Xenon to Present at the Goldman Sachs 46th Annual Global Healthcare Conference (GlobeNewswire EN)
|
|
|
VANCOUVER, British Columbia and BOSTON, June 03, 2025 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to discovering, developing, and delivering life-changing therapeutics for patients in need, today announced that the company will present at the Goldman Sachs 46th Annual Global Healthcare Conference taking place in Miami, FL, from June 9-11, 2025....
|
|
|
30.05.25 - 22:03
|
Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire EN)
|
|
|
VANCOUVER, British Columbia and BOSTON, May 30, 2025 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to discovering, developing, and delivering life-changing therapeutics for patients in need, today announced equity inducement grants to seven new non-officer employees consisting of an aggregate of 53,550 share options. All of the foregoing share options were approved by the Compensation Committee of the Company's Board of Directors with an effective date of May 29, 2025 and were granted as inducements material to the employees entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4)....
|
|
|
14.05.25 - 22:03
|
Xenon to Present at the 2025 RBC Capital Markets Global Healthcare Conference (GlobeNewswire EN)
|
|
|
VANCOUVER, British Columbia and BOSTON, May 14, 2025 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to discovering, developing, and delivering life-changing therapeutics for patients in need, today announced that the company will present at the 2025 RBC Capital Markets Global Healthcare Conference taking place in New York, NY from May 20-21, 2025....
|
|
|
|
|
|
|
05.05.25 - 22:03
|
Xenon to Report Q1 2025 Financial Results on May 12, 2025 (GlobeNewswire EN)
|
|
|
VANCOUVER, British Columbia and BOSTON, May 05, 2025 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to discovering, developing, and delivering life-changing therapeutics for patients in need, today announced it will report its first quarter 2025 financial results and provide a business update after the close of U.S. financial markets on Monday, May 12, 2025....
|
|
|
|
|
02.05.25 - 22:45
|
Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire EN)
|
|
|
VANCOUVER, British Columbia and BOSTON, May 02, 2025 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to discovering, developing, and delivering life-changing therapeutics for patients in need, today announced equity inducement grants to four new non-officer employees consisting of an aggregate of 78,600 share options and 1,800 performance share units (“PSUs”). All of the foregoing share options and PSUs were approved by the Compensation Committee of the Company's Board of Directors with an effective date of May 2, 2025 and were granted as inducements material to the employees entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4)....
|
|
|
04.04.25 - 14:33
|
Xenon to Showcase Long-Term 36-Month Azetukalner Data at AAN 2025 (GlobeNewswire EN)
|
|
|
VANCOUVER, British Columbia and BOSTON, April 04, 2025 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to discovering, developing, and delivering life-changing therapeutics for patients in need, today announced multiple presentations at the upcoming American Academy of Neurology Annual Meeting (AAN 2025), taking place April 5-9, 2025 in San Diego, CA. Three posters will be presented, including long-term data from the ongoing X-TOLE open-label extension (OLE) study of azetukalner in patients with focal onset seizures (FOS). The Company will also present an exploratory efficacy analysis of FOS seizure subtypes from the X-TOLE study, as well as patient survey findings about the mental health and comorbidity burdens of FOS....
|
|
|
12.03.25 - 21:03
|
Xenon to Present at Stifel 2025 Virtual CNS Forum (GlobeNewswire EN)
|
|
|
VANCOUVER, British Columbia and BOSTON, March 12, 2025 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to discovering, developing, and delivering life-changing therapeutics for patients in need, today announced that the company will present at the Stifel 2025 Virtual CNS Forum taking place from March 18-19, 2025....
|
|
|
25.02.25 - 22:03
|
Xenon to Present at the 45th Annual TD Cowen Healthcare Conference (GlobeNewswire EN)
|
|
|
VANCOUVER, British Columbia and BOSTON, Feb. 25, 2025 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to discovering, developing, and delivering life-changing therapeutics for patients in need, today announced that the company will present at the 45th Annual TD Cowen Healthcare Conference taking place in Boston, MA from March 3-5, 2025....
|
|
|
20.02.25 - 22:03
|
Xenon to Report Q4 and Full Year 2024 Financial Results on February 27, 2025 (GlobeNewswire EN)
|
|
|
VANCOUVER, British Columbia and BOSTON, Feb. 20, 2025 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to discovering, developing, and delivering life-changing therapeutics for patients in need, today announced it will report its fourth quarter 2024 financial results after the close of U.S. financial markets on Thursday, February 27, 2025....
|
|
|
|
|
|
|
|
|
07.01.25 - 14:33
|
Xenon to Present at the 43rd Annual J.P. Morgan Healthcare Conference (GlobeNewswire EN)
|
|
|
VANCOUVER, British Columbia and BOSTON, Jan. 07, 2025 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to discovering, developing, and delivering life-changing therapeutics for patients in need, today announced that the company will present at the 43rd Annual J.P. Morgan Healthcare Conference taking place in San Francisco, CA from January 13-16, 2025....
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
